Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

Transcriptome of 17Β-Hydroxysteroid Dehydrogenase Type 2 Plays Both Hormone-Dependent and Hormone-Independent Roles in MCF-7 Breast Cancer Cells.

Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.

Expression of 17β-hydroxysteroid dehydrogenase type 2 in breast cancer and adjacent non-malignant tissue: a correlation to clinical factors

Data from Functional Silencing of <i>hsd17b2</i> in Prostate Cancer Promotes Disease Progression

Ectopic Expression of HSDL2 is Related to Cell Proliferation and Prognosis in Breast Cancer

Human 3 Alpha-Hydroxysteroid Dehydrogenase Type 3: Structural Clues Of 5 Alpha-Dht Reverse Binding And Enzyme Down-Regulation Decreasing Mcf7 Cell Growth

Expression of 17β-hydroxysteroid dehydrogenase type5 in breast cancer and adjacent non-malignant tissue and the relationship between it and clinical factors

Differential Regulation of Human 3β-Hydroxysteroid Dehydrogenase Type 2 for Steroid Hormone Biosynthesis by Starvation and Cyclic Amp Stimulation: Studies in the Human Adrenal NCI-H295R Cell Model

The Contribution Of 17beta-Hydroxysteroid Dehydrogenase Type 1 To The Estradiol-Estrone Ratio In Estrogen-Sensitive Breast Cancer Cells

Proteomic analysis of holocarboxylase synthetase deficient-MDA-MB-231 breast cancer cells revealed the biochemical changes associated with cell death, impaired growth signaling, and metabolism

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors

Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase.

SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone and androgen receptors-mediated transactivation

Substrate inhibition of 17β-HSD1 in living cells and regulation of 17β-HSD7 by 17β-HSD1 knockdown

Dihydrotestosterone Induces P27 Degradation Via Direct Binding with Skp2 in Ovarian and Breast Cancer

Knockdown of HSDL2 Inhibits Lung Adenocarcinoma Progression Via Down-Regulating AKT2 Expression

11β-hydroxysteroid dehydrogenases-2 decreases the apoptosis of MC3T3/MLO-Y4 cells induced by glucocorticoids

17-Beta-hydroxysteroid Dehydrogenase 13 Inhibits the Progression and Recurrence of Hepatocellular Carcinoma.

HSD17B6 Downregulation Predicts Poor Prognosis and Drives Tumor Progression Via Activating Akt Signaling Pathway in Lung Adenocarcinoma